Company Information

  

Address: 80 W. LANCASTER AVENUE
SUITE 300 
City: DEVON 
State: PA 
Zip Code: 19333 
Telephone: 484-581-7505 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Unless the context indicates otherwise, the terms "Zynerba," "Zynerba Pharmaceuticals," "we," "us," "our," "our company" and "our business" refer to Zynerba Pharmaceuticals, Inc. Company Overview We are a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare (meeting the U.S. Food and Drug Administration's, or FDA's, designation of an orphan disease, affecting fewer than 200,000 people in the United States) and near-rare (affecting fewer than one million people in the United States) neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. We are currently evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-2.79NAN/E
12/2017-2.48NAN/E
09/2017-2.59NAN/E
06/2017-2.63NAN/E
03/2017-2.69NAN/E
12/2016-2.58NAN/E
09/2016-2.31NAN/E
06/2016-1.86NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.23Total Liab/Total Assets0.12
Net Inc/Total Assets-0.46Total Liab/Inv Cap0.13
Net Inc/Inv Cap-0.52Total Liab/Comm Equity0.06
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio9.17
Inventory TurnoverNACurrent Ratio9.17
Inventory Day SalesNANet Rec/Curr Assets0.06
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.42 2.38 2.80 2.63
Operating Income -12.40 -8.20 -8.55 -8.37
Interest Exp NA NA NA NA
Pretax Income -12.31 -8.12 -8.31 -8.32
Other Income 0.09 0.09 0.24 0.04
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -12.31 -8.12 -8.31 -8.32

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 52.13 62.51 66.25 70.18
Receivables - Total 4.04 3.98 3.62 3.97
Inventories - Total NA NA NA NA
Total Current Assets 57.97 68.23 72.88 76.46
Net Property, Plant & Equipment 0.16 0.16 0.19 0.18
Total Assets 59.90 69.05 73.07 79.09
Liabilities        
Accounts Payable 8.74 7.27 7.60 7.03
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 8.91 7.44 8.43 7.86
Long-Term Debt NA NA NA NA
Total Liabilities 9.57 8.10 8.43 7.86
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -90.29 -77.98 -69.86 -61.55
Treasury Stock NA NA NA NA
Total Stockholders' Equity 50.33 60.95 64.64 71.23
Total Liabilities and Stockholders' Equity 59.90 69.05 73.07 79.09

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -10.36 -6.71 -3.81 -7.67
Net Cash Provided by Investing Activities -0.02 -0.02 -0.01 -0.01
Net Cash Provided by Financing Activities 0.00 3.00 -0.11 0.37

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.94-0.64--
12/20140.81-5.67--
12/20150.28-12.55-2.82
12/20160.01-23.39-2.58
12/20170.00-32.01-2.48
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18733,02222.28




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.